Amtagvi (lifileucel) - MEDICAID - VIRGINIA

Amtagvi (lifileucel) is covered as an autologous tumor‑infiltrating lymphocyte (TIL) adoptive cell therapy administered as a single‑dose infusion for adults with unresectable or metastatic melanoma. Coverage is limited to individuals ≥18 who have failed prior PD‑1 blockade (and, if BRAF V600‑mutant, prior BRAF inhibitor with or without a MEK inhibitor), excludes pregnancy/breastfeeding and those unwilling to use contraception, and requires medical director review and coordination through the Corporate Transplant Department; member-specific coverage documents may further modify eligibility.

"Amtagvi is an adoptive cell therapy with tumor-infiltrating lymphocytes (TILs)."

Sign up to see full coverage criteria, indications, and limitations.